Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Pharmexa
Woman and Man Max 99 years
Pharmexa A/S
Update Il y a 4 ans
“Heptovax” - Ensayo de fase II, abierto, para evaluar la seguridad y la eficacia de GV1001 para el carcinoma hepatocelular avanzado. (CHC)
Investigar la eficacia de GV1001 en el CHC localmente avanzado o metastásico.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pharmexa A/S
Update Il y a 4 ans
“Primovax” – A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-resectable Pancreatic Cancer
To investigate the efficacy of GV1001 in sequential combination with gemcitabine in locally advanced or metastatic adenocarcinoma of the pancreas.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years and 75 years
Pharmexa
Update Il y a 4 ans
Pharmexa PRIMOVAX : Essai de phase 3 randomisé comparant un traitement séquentiel associant GV001et gemcitabine à gemcitabine seul chez des patients ayant un cancer du pancréas. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.
Country
France
organs
Pancréas
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman Max 99 years
Pharmexa A/S
Update Il y a 4 ans
A Phase II trial evaluating the immunological and clinical efficay and safety of HER-2 Protein Autovac(TM) monotherapy in patients with metastatic breast cancer
The primary objective of the trial is to demonstrate evidence of clinical efficacy of HER-2 Protein AutoVac(TM), that is the number of evaluable patients with evidence of clinical benefit, defined as:...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Pharmexa A/S
Update Il y a 4 ans
A Phase II trial evaluating the immunological and clinical efficacy and safety of HER-2 Protein AutoVac(TM) and Stimulon® Adjuvant QS-21 monotherapy in patients with metastatic breast cancer
The primary objective of the trial is to demonstrate evidence of clinical efficacy of HER-2 Protein AutoVac(TM)/QS-21, that is the number of evaluable patients with evidence of clinical benefit, defin...
Country
None
organs
None
Specialty
None
unknown
More information